KUALA LUMPUR (Aug 14): TMC Life Sciences Bhd (KL:TMCLIFE) nearly doubled its net profit for the fourth financial quarter ended June 30, 2026 (4QFY2026) from a year earlier on higher revenue and improved cost efficiency.

The healthcare group reported a net profit of RM4.65 million in 4QFY2026, up 91.8% from RM2.42 million a year earlier, according to a Bursa Malaysia filing on Friday.

Revenue for the period increased 6.5% to RM99.35 million from RM93.27 million a year earlier. On a quarter-on-quarter basis, revenue rose 11% from RM89.70 million in 3QFY2026.

For the full financial year (FY2026), TMC Life Sciences saw its net profit jump nearly fivefold to RM17.38 million from RM3.61 million in FY2025, while revenue grew 13.7% to RM393.03 million from RM345.54 million.

The group attributed its performance to the successful recruitment of healthcare professionals, additional bed capacity and services, higher case intensity, as well as continued marketing efforts to strengthen its local and international brands.

Subject to shareholders' approval at its upcoming annual general meeting, TMC Life Sciences has recommended a first and final single-tier dividend of 0.5763 sen per share for FY2026, amounting to RM10.04 million, compared with 0.1863 sen per share, or RM3.25 million, for FY2025.

On its outlook, the group said the impact of global geopolitical tensions on supply chain disruptions remained contained, although inflationary pressures remained a concern. It said operational efficiency and cost optimisation measures would help mitigate these pressures.

For FY2027, TMC Life Sciences noted that evolving payor dynamics continue to shape the private healthcare landscape, with insurers and corporate customers placing greater emphasis on affordability and value-based outcomes. In response, the group said it is executing a value-based care strategy.

"This approach focuses on delivering high-quality and efficient clinical outcomes in a financially sustainable manner, thereby ensuring we remain as preferred partner for insurers while maintaining our commitment to excellence in patient care," it said.

The group also plans to expand key specialties, strengthen its presence in the corporate segment, broaden its international patient mix and tap regional demand for fertility treatment.

Shares of TMC Life Sciences closed unchanged at 46.5 sen on Friday, valuing the group at RM809.98 million. The stock has gained more than 13% over the past year.